APO Research
Talk to an analyst

APO RESEARCH · REPORT

Treating Chronic Myeloid Leukemia by Phase

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Treating Chronic Myeloid Leukemia by Phase Market Outlook and Growth Opportunities 2026

27 December 2025208 pages

Choose your research edition.

Industry ResearchTreating Chronic Myeloid Leukemia by Phase Industry Research Report 2026133 pages · $2,950 USDIndustry Growth & TrendsGlobal Treating Chronic Myeloid Leukemia by Phase Industry Growth and Trends Forecast to 2032114 pages · $3,450 USDMarket StructureGlobal Treating Chronic Myeloid Leukemia by Phase Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Treating Chronic Myeloid Leukemia by Phase Market Outlook and Growth Opportunities 2026208 pages · $4,250 USDMarket Analysis & ForecastGlobal Treating Chronic Myeloid Leukemia by Phase Market Analysis and Forecast 2026-2032208 pages · $4,950 USD

Market perspective

The global Treating Chronic Myeloid Leukemia by Phase market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Treating Chronic Myeloid Leukemia by Phase is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Treating Chronic Myeloid Leukemia by Phase is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Treating Chronic Myeloid Leukemia by Phase is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Treating Chronic Myeloid Leukemia by Phase market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Treating Chronic Myeloid Leukemia by Phase market include Chia Tai Tianqing Pharmaceutical, Suzhou Thery Pharmaceutical, CSPC Ouyi Pharmaceutical, Qilu Pharmaceutical, Lunan Pharmaceutical, Hansoh Pharmaceutical, Teva, Takeda Pharmaceuticals and Sun Pharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Treating Chronic Myeloid Leukemia by Phase market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Treating Chronic Myeloid Leukemia by Phase and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Treating Chronic Myeloid Leukemia by Phase revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Treating Chronic Myeloid Leukemia by Phase market.

Treating Chronic Myeloid Leukemia by Phase Segment by Company

Chia Tai Tianqing Pharmaceutical

Suzhou Thery Pharmaceutical

CSPC Ouyi Pharmaceutical

Qilu Pharmaceutical

Lunan Pharmaceutical

Hansoh Pharmaceutical

Teva

Takeda Pharmaceuticals

Sun Pharmaceuticals

Sawai Pharmaceutical

Pfizer

Novartis

Mylan

Lupin

Hetero

Eugia Pharma

Dr. Reddy's Laboratories

Bristol Myers Squibb

Apotex

Treating Chronic Myeloid Leukemia by Phase Segment by Type

Blast Phase

Accelerated Phase

Chronic Phase

Treating Chronic Myeloid Leukemia by Phase Segment by Application

Hospitals

Clinics

Others

Treating Chronic Myeloid Leukemia by Phase Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Treating Chronic Myeloid Leukemia by Phase status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Treating Chronic Myeloid Leukemia by Phase key companies, revenue, market share, and recent developments.

3. To split the Treating Chronic Myeloid Leukemia by Phase breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Treating Chronic Myeloid Leukemia by Phase market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Treating Chronic Myeloid Leukemia by Phase significant trends, drivers, influence factors in global and regions.

6. To analyze Treating Chronic Myeloid Leukemia by Phase competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Treating Chronic Myeloid Leukemia by Phase market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Treating Chronic Myeloid Leukemia by Phase and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Treating Chronic Myeloid Leukemia by Phase.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Treating Chronic Myeloid Leukemia by Phase industry.

Chapter 3: Detailed analysis of Treating Chronic Myeloid Leukemia by Phase company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Treating Chronic Myeloid Leukemia by Phase in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Treating Chronic Myeloid Leukemia by Phase in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Treating Chronic Myeloid Leukemia by Phase Industry Trends Table 2. Treating Chronic Myeloid Leukemia by Phase Industry Drivers Table 3. Treating Chronic Myeloid Leukemia by Phase Industry Opportunities and Challenges Table 4. Treating Chronic Myeloid Leukemia by Phase Industry Restraints Table 5. Global Treating Chronic Myeloid Leukemia by Phase Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Treating Chronic Myeloid Leukemia by Phase Revenue Share by Company (2021-2026) Table 7. Global Treating Chronic Myeloid Leukemia by Phase Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Treating Chronic Myeloid Leukemia by Phase Key Company Manufacturing Base & Headquarters Table 9. Global Treating Chronic Myeloid Leukemia by Phase Company, Product Type & Application Table 10. Global Treating Chronic Myeloid Leukemia by Phase Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Treating Chronic Myeloid Leukemia by Phase by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Blast Phase Table 15. Significant Companies of Accelerated Phase Table 16. Significant Companies of Chronic Phase Table 17. Global Treating Chronic Myeloid Leukemia by Phase Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 18. Global Treating Chronic Myeloid Leukemia by Phase Sales Value by Type (2021-2026) & (US$ Million) Table 19. Global Treating Chronic Myeloid Leukemia by Phase Sales Value by Type (2027-2032) & (US$ Million) Table 20. Global Treating Chronic Myeloid Leukemia by Phase Sales Value Share by Type (2021-2026) Table 21. Global Treating Chronic Myeloid Leukemia by Phase Sales Value Share by Type (2027-2032) Table 22. Significant Companies of Hospitals Table 23. Significant Companies of Clinics Table 24. Significant Companies of Others Table 25. Global Treating Chronic Myeloid Leukemia by Phase Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Treating Chronic Myeloid Leukemia by Phase Sales Value by Application (2021-2026) & (US$ Million) Table 27. Global Treating Chronic Myeloid Leukemia by Phase Sales Value by Application (2027-2032) & (US$ Million) Table 28. Global Treating Chronic Myeloid Leukemia by Phase Sales Value Share by Application (2021-2026) Table 29. Global Treating Chronic Myeloid Leukemia by Phase Sales Value Share by Application (2027-2032) Table 30. Global Treating Chronic Myeloid Leukemia by Phase Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Treating Chronic Myeloid Leukemia by Phase Sales Value by Region (2021-2026) & (US$ Million) Table 32. Global Treating Chronic Myeloid Leukemia by Phase Sales Value Share by Region (2021-2026) Table 33. Global Treating Chronic Myeloid Leukemia by Phase Sales Value by Region (2027-2032) & (US$ Million) Table 34. Global Treating Chronic Myeloid Leukemia by Phase Sales Value Share by Region (2027-2032) Table 35. Global Treating Chronic Myeloid Leukemia by Phase Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Treating Chronic Myeloid Leukemia by Phase Sales Value by Country (2021-2026) & (US$ Million) Table 37. Global Treating Chronic Myeloid Leukemia by Phase Sales Value Market Share by Country (2021-2026) Table 38. Global Treating Chronic Myeloid Leukemia by Phase Sales Value by Country (2027-2032) & (US$ Million) Table 39. Global Treating Chronic Myeloid Leukemia by Phase Sales Value Market Share by Country (2027-2032) Table 40. Chia Tai Tianqing Pharmaceutical Company Information Table 41. Chia Tai Tianqing Pharmaceutical Business Overview Table 42. Chia Tai Tianqing Pharmaceutical Treating Chronic Myeloid Leukemia by Phase Revenue (US$ Million) and Gross Margin (2021-2026) Table 43. Chia Tai Tianqing Pharmaceutical Treating Chronic Myeloid Leukemia by Phase Product Portfolio Table 44. Chia Tai Tianqing Pharmaceutical Recent Development Table 45. Suzhou Thery Pharmaceutical Company Information Table 46. Suzhou Thery Pharmaceutical Business Overview Table 47. Suzhou Thery Pharmaceutical Treating Chronic Myeloid Leukemia by Phase Revenue (US$ Million) and Gross Margin (2021-2026) Table 48. Suzhou Thery Pharmaceutical Treating Chronic Myeloid Leukemia by Phase Product Portfolio Table 49. Suzhou Thery Pharmaceutical Recent Development Table 50. CSPC Ouyi Pharmaceutical Company Information Table 51. CSPC Ouyi Pharmaceutical Business Overview Table 52. CSPC Ouyi Pharmaceutical Treating Chronic Myeloid Leukemia by Phase Revenue (US$ Million) and Gross Margin (2021-2026) Table 53. CSPC Ouyi Pharmaceutical Treating Chronic Myeloid Leukemia by Phase Product Portfolio Table 54. CSPC Ouyi Pharmaceutical Recent Development Table 55. Qilu Pharmaceutical Company Information Table 56. Qilu Pharmaceutical Business Overview Table 57. Qilu Pharmaceutical Treating Chronic Myeloid Leukemia by Phase Revenue (US$ Million) and Gross Margin (2021-2026) Table 58. Qilu Pharmaceutical Treating Chronic Myeloid Leukemia by Phase Product Portfolio Table 59. Qilu Pharmaceutical Recent Development Table 60. Lunan Pharmaceutical Company Information Table 61. Lunan Pharmaceutical Business Overview Table 62. Lunan Pharmaceutical Treating Chronic Myeloid Leukemia by Phase Revenue (US$ Million) and Gross Margin (2021-2026) Table 63. Lunan Pharmaceutical Treating Chronic Myeloid Leukemia by Phase Product Portfolio Table 64. Lunan Pharmaceutical Recent Development Table 65. Hansoh Pharmaceutical Company Information Table 66. Hansoh Pharmaceutical Business Overview Table 67. Hansoh Pharmaceutical Treating Chronic Myeloid Leukemia by Phase Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Hansoh Pharmaceutical Treating Chronic Myeloid Leukemia by Phase Product Portfolio Table 69. Hansoh Pharmaceutical Recent Development Table 70. Teva Company Information Table 71. Teva Business Overview Table 72. Teva Treating Chronic Myeloid Leukemia by Phase Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. Teva Treating Chronic Myeloid Leukemia by Phase Product Portfolio Table 74. Teva Recent Development Table 75. Takeda Pharmaceuticals Company Information Table 76. Takeda Pharmaceuticals Business Overview Table 77. Takeda Pharmaceuticals Treating Chronic Myeloid Leukemia by Phase Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Takeda Pharmaceuticals Treating Chronic Myeloid Leukemia by Phase Product Portfolio Table 79. Takeda Pharmaceuticals Recent Development Table 80. Sun Pharmaceuticals Company Information Table 81. Sun Pharmaceuticals Business Overview Table 82. Sun Pharmaceuticals Treating Chronic Myeloid Leukemia by Phase Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. Sun Pharmaceuticals Treating Chronic Myeloid Leukemia by Phase Product Portfolio Table 84. Sun Pharmaceuticals Recent Development Table 85. Sawai Pharmaceutical Company Information Table 86. Sawai Pharmaceutical Business Overview Table 87. Sawai Pharmaceutical Treating Chronic Myeloid Leukemia by Phase Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. Sawai Pharmaceutical Treating Chronic Myeloid Leukemia by Phase Product Portfolio Table 89. Sawai Pharmaceutical Recent Development Table 90. Pfizer Company Information Table 91. Pfizer Business Overview Table 92. Pfizer Treating Chronic Myeloid Leukemia by Phase Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 93. Pfizer Treating Chronic Myeloid Leukemia by Phase Product Portfolio Table 94. Pfizer Recent Development Table 95. Novartis Company Information Table 96. Novartis Business Overview Table 97. Novartis Treating Chronic Myeloid Leukemia by Phase Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 98. Novartis Treating Chronic Myeloid Leukemia by Phase Product Portfolio Table 99. Novartis Recent Development Table 100. Mylan Company Information Table 101. Mylan Business Overview Table 102. Mylan Treating Chronic Myeloid Leukemia by Phase Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 103. Mylan Treating Chronic Myeloid Leukemia by Phase Product Portfolio Table 104. Mylan Recent Development Table 105. Lupin Company Information Table 106. Lupin Business Overview Table 107. Lupin Treating Chronic Myeloid Leukemia by Phase Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 108. Lupin Treating Chronic Myeloid Leukemia by Phase Product Portfolio Table 109. Lupin Recent Development Table 110. Hetero Company Information Table 111. Hetero Business Overview Table 112. Hetero Treating Chronic Myeloid Leukemia by Phase Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 113. Hetero Treating Chronic Myeloid Leukemia by Phase Product Portfolio Table 114. Hetero Recent Development Table 115. Eugia Pharma Company Information Table 116. Eugia Pharma Business Overview Table 117. Eugia Pharma Treating Chronic Myeloid Leukemia by Phase Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 118. Eugia Pharma Treating Chronic Myeloid Leukemia by Phase Product Portfolio Table 119. Eugia Pharma Recent Development Table 120. Dr. Reddy's Laboratories Company Information Table 121. Dr. Reddy's Laboratories Business Overview Table 122. Dr. Reddy's Laboratories Treating Chronic Myeloid Leukemia by Phase Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 123. Dr. Reddy's Laboratories Treating Chronic Myeloid Leukemia by Phase Product Portfolio Table 124. Dr. Reddy's Laboratories Recent Development Table 125. Bristol Myers Squibb Company Information Table 126. Bristol Myers Squibb Business Overview Table 127. Bristol Myers Squibb Treating Chronic Myeloid Leukemia by Phase Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 128. Bristol Myers Squibb Treating Chronic Myeloid Leukemia by Phase Product Portfolio Table 129. Bristol Myers Squibb Recent Development Table 130. Apotex Company Information Table 131. Apotex Business Overview Table 132. Apotex Treating Chronic Myeloid Leukemia by Phase Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 133. Apotex Treating Chronic Myeloid Leukemia by Phase Product Portfolio Table 134. Apotex Recent Development Table 135. Research Programs/Design for This Report Table 136. Authors List of This Report Table 137. Secondary Sources Table 138. Primary Sources List of Figures Figure 1. Treating Chronic Myeloid Leukemia by Phase Product Image Figure 2. Global Treating Chronic Myeloid Leukemia by Phase Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Treating Chronic Myeloid Leukemia by Phase Market Size (2021-2032) & (US$ Million) Figure 4. Global Treating Chronic Myeloid Leukemia by Phase Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Blast Phase Image Figure 8. Accelerated Phase Image Figure 9. Chronic Phase Image Figure 10. Global Treating Chronic Myeloid Leukemia by Phase Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 11. Global Treating Chronic Myeloid Leukemia by Phase Sales Value Share 2021 VS 2025 VS 2032 Figure 12. Global Treating Chronic Myeloid Leukemia by Phase Sales Value Share by Type (2021-2032) Figure 13. Hospitals Image Figure 14. Clinics Image Figure 15. Others Image Figure 16. Global Treating Chronic Myeloid Leukemia by Phase Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Treating Chronic Myeloid Leukemia by Phase Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Treating Chronic Myeloid Leukemia by Phase Sales Value Share by Application (2021-2032) Figure 19. Global Treating Chronic Myeloid Leukemia by Phase Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 20. Global Treating Chronic Myeloid Leukemia by Phase Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 21. North America Treating Chronic Myeloid Leukemia by Phase Sales Value (2021-2032) & (US$ Million) Figure 22. North America Treating Chronic Myeloid Leukemia by Phase Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Europe Treating Chronic Myeloid Leukemia by Phase Sales Value (2021-2032) & (US$ Million) Figure 24. Europe Treating Chronic Myeloid Leukemia by Phase Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Asia-Pacific Treating Chronic Myeloid Leukemia by Phase Sales Value (2021-2032) & (US$ Million) Figure 26. Asia-Pacific Treating Chronic Myeloid Leukemia by Phase Sales Value Share by Country (%), 2025 VS 2032 Figure 27. South America Treating Chronic Myeloid Leukemia by Phase Sales Value (2021-2032) & (US$ Million) Figure 28. South America Treating Chronic Myeloid Leukemia by Phase Sales Value Share by Country (%), 2025 VS 2032 Figure 29. Middle East & Africa Treating Chronic Myeloid Leukemia by Phase Sales Value (2021-2032) & (US$ Million) Figure 30. Middle East & Africa Treating Chronic Myeloid Leukemia by Phase Sales Value Share by Country (%), 2025 VS 2032 Figure 31. USA Treating Chronic Myeloid Leukemia by Phase Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 32. USA Treating Chronic Myeloid Leukemia by Phase Sales Value Share by Type, 2025 VS 2032 & (%) Figure 33. USA Treating Chronic Myeloid Leukemia by Phase Sales Value Share by Application, 2025 VS 2032 & (%) Figure 34. Canada Treating Chronic Myeloid Leukemia by Phase Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 35. Canada Treating Chronic Myeloid Leukemia by Phase Sales Value Share by Type, 2025 VS 2032 & (%) Figure 36. Canada Treating Chronic Myeloid Leukemia by Phase Sales Value Share by Application, 2025 VS 2032 & (%) Figure 37. Mexico Treating Chronic Myeloid Leukemia by Phase Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. Mexico Treating Chronic Myeloid Leukemia by Phase Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. Mexico Treating Chronic Myeloid Leukemia by Phase Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Germany Treating Chronic Myeloid Leukemia by Phase Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Germany Treating Chronic Myeloid Leukemia by Phase Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Germany Treating Chronic Myeloid Leukemia by Phase Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. France Treating Chronic Myeloid Leukemia by Phase Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. France Treating Chronic Myeloid Leukemia by Phase Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. France Treating Chronic Myeloid Leukemia by Phase Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. U.K. Treating Chronic Myeloid Leukemia by Phase Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. U.K. Treating Chronic Myeloid Leukemia by Phase Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. U.K. Treating Chronic Myeloid Leukemia by Phase Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Italy Treating Chronic Myeloid Leukemia by Phase Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Italy Treating Chronic Myeloid Leukemia by Phase Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Italy Treating Chronic Myeloid Leukemia by Phase Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Spain Treating Chronic Myeloid Leukemia by Phase Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Spain Treating Chronic Myeloid Leukemia by Phase Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Spain Treating Chronic Myeloid Leukemia by Phase Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Russia Treating Chronic Myeloid Leukemia by Phase Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Russia Treating Chronic Myeloid Leukemia by Phase Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Russia Treating Chronic Myeloid Leukemia by Phase Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Netherlands Treating Chronic Myeloid Leukemia by Phase Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Netherlands Treating Chronic Myeloid Leukemia by Phase Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Netherlands Treating Chronic Myeloid Leukemia by Phase Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Nordic Countries Treating Chronic Myeloid Leukemia by Phase Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Nordic Countries Treating Chronic Myeloid Leukemia by Phase Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Nordic Countries Treating Chronic Myeloid Leukemia by Phase Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. China Treating Chronic Myeloid Leukemia by Phase Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. China Treating Chronic Myeloid Leukemia by Phase Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. China Treating Chronic Myeloid Leukemia by Phase Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Japan Treating Chronic Myeloid Leukemia by Phase Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Japan Treating Chronic Myeloid Leukemia by Phase Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Japan Treating Chronic Myeloid Leukemia by Phase Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. South Korea Treating Chronic Myeloid Leukemia by Phase Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. South Korea Treating Chronic Myeloid Leukemia by Phase Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. South Korea Treating Chronic Myeloid Leukemia by Phase Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. India Treating Chronic Myeloid Leukemia by Phase Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. India Treating Chronic Myeloid Leukemia by Phase Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. India Treating Chronic Myeloid Leukemia by Phase Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Australia Treating Chronic Myeloid Leukemia by Phase Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Australia Treating Chronic Myeloid Leukemia by Phase Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Australia Treating Chronic Myeloid Leukemia by Phase Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Southeast Asia Treating Chronic Myeloid Leukemia by Phase Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Southeast Asia Treating Chronic Myeloid Leukemia by Phase Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Southeast Asia Treating Chronic Myeloid Leukemia by Phase Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Brazil Treating Chronic Myeloid Leukemia by Phase Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Brazil Treating Chronic Myeloid Leukemia by Phase Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Brazil Treating Chronic Myeloid Leukemia by Phase Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Argentina Treating Chronic Myeloid Leukemia by Phase Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Argentina Treating Chronic Myeloid Leukemia by Phase Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Argentina Treating Chronic Myeloid Leukemia by Phase Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Chile Treating Chronic Myeloid Leukemia by Phase Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Chile Treating Chronic Myeloid Leukemia by Phase Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Chile Treating Chronic Myeloid Leukemia by Phase Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Colombia Treating Chronic Myeloid Leukemia by Phase Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Colombia Treating Chronic Myeloid Leukemia by Phase Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Colombia Treating Chronic Myeloid Leukemia by Phase Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Peru Treating Chronic Myeloid Leukemia by Phase Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Peru Treating Chronic Myeloid Leukemia by Phase Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Peru Treating Chronic Myeloid Leukemia by Phase Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Saudi Arabia Treating Chronic Myeloid Leukemia by Phase Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Saudi Arabia Treating Chronic Myeloid Leukemia by Phase Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Treating Chronic Myeloid Leukemia by Phase Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Israel Treating Chronic Myeloid Leukemia by Phase Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Israel Treating Chronic Myeloid Leukemia by Phase Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Israel Treating Chronic Myeloid Leukemia by Phase Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. UAE Treating Chronic Myeloid Leukemia by Phase Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. UAE Treating Chronic Myeloid Leukemia by Phase Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. UAE Treating Chronic Myeloid Leukemia by Phase Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Turkey Treating Chronic Myeloid Leukemia by Phase Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Turkey Treating Chronic Myeloid Leukemia by Phase Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Turkey Treating Chronic Myeloid Leukemia by Phase Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Iran Treating Chronic Myeloid Leukemia by Phase Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Iran Treating Chronic Myeloid Leukemia by Phase Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Iran Treating Chronic Myeloid Leukemia by Phase Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Egypt Treating Chronic Myeloid Leukemia by Phase Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Egypt Treating Chronic Myeloid Leukemia by Phase Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Egypt Treating Chronic Myeloid Leukemia by Phase Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Years Considered Figure 116. Research Process Figure 117. Key Executives Interviewed

Scope & coverage.

Types
  • Blast Phase
  • Accelerated Phase
  • Chronic Phase
Applications
  • Hospitals
  • Clinics
  • Others
Companies covered
  • Chia Tai Tianqing Pharmaceutical
  • Suzhou Thery Pharmaceutical
  • CSPC Ouyi Pharmaceutical
  • Qilu Pharmaceutical
  • Lunan Pharmaceutical
  • Hansoh Pharmaceutical
  • Teva
  • Takeda Pharmaceuticals
  • Sun Pharmaceuticals
  • Sawai Pharmaceutical
  • Pfizer
  • Novartis
  • Mylan
  • Lupin
  • Hetero
  • Eugia Pharma
  • Dr. Reddy's Laboratories
  • Bristol Myers Squibb
  • Apotex

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Treating Chronic Myeloid Leukemia by Phase Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Treating Chronic Myeloid Leukemia by Phase Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Treating Chronic Myeloid Leukemia by Phase Market Dynamics
  1. 2.1 Treating Chronic Myeloid Leukemia by Phase Industry Trends
  2. 2.2 Treating Chronic Myeloid Leukemia by Phase Industry Drivers
  3. 2.3 Treating Chronic Myeloid Leukemia by Phase Industry Opportunities and Challenges
  4. 2.4 Treating Chronic Myeloid Leukemia by Phase Industry Restraints
3 Treating Chronic Myeloid Leukemia by Phase Market by Company
  1. 3.1 Global Treating Chronic Myeloid Leukemia by Phase Company Revenue Ranking in 2025
  2. 3.2 Global Treating Chronic Myeloid Leukemia by Phase Revenue by Company (2021-2026)
  3. 3.3 Global Treating Chronic Myeloid Leukemia by Phase Company Ranking (2024-2026)
  4. 3.4 Global Treating Chronic Myeloid Leukemia by Phase Company Manufacturing Base and Headquarters
  5. 3.5 Global Treating Chronic Myeloid Leukemia by Phase Company Product Type and Application
  6. 3.6 Global Treating Chronic Myeloid Leukemia by Phase Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Treating Chronic Myeloid Leukemia by Phase Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Treating Chronic Myeloid Leukemia by Phase Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Treating Chronic Myeloid Leukemia by Phase Market by Type
  1. 4.1 Treating Chronic Myeloid Leukemia by Phase Type Introduction
  2. 4.1.1 Blast Phase
  3. 4.1.2 Accelerated Phase
  4. 4.1.3 Chronic Phase
  5. 4.2 Global Treating Chronic Myeloid Leukemia by Phase Sales Value by Type
  6. 4.2.1 Global Treating Chronic Myeloid Leukemia by Phase Sales Value by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Treating Chronic Myeloid Leukemia by Phase Sales Value by Type (2021-2032)
  8. 4.2.3 Global Treating Chronic Myeloid Leukemia by Phase Sales Value Share by Type (2021-2032)
5 Treating Chronic Myeloid Leukemia by Phase Market by Application
  1. 5.1 Treating Chronic Myeloid Leukemia by Phase Application Introduction
  2. 5.1.1 Hospitals
  3. 5.1.2 Clinics
  4. 5.1.3 Others
  5. 5.2 Global Treating Chronic Myeloid Leukemia by Phase Sales Value by Application
  6. 5.2.1 Global Treating Chronic Myeloid Leukemia by Phase Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Treating Chronic Myeloid Leukemia by Phase Sales Value by Application (2021-2032)
  8. 5.2.3 Global Treating Chronic Myeloid Leukemia by Phase Sales Value Share by Application (2021-2032)
6 Treating Chronic Myeloid Leukemia by Phase Regional Value Analysis
  1. 6.1 Global Treating Chronic Myeloid Leukemia by Phase Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Treating Chronic Myeloid Leukemia by Phase Sales Value by Region (2021-2032)
  3. 6.2.1 Global Treating Chronic Myeloid Leukemia by Phase Sales Value by Region: 2021-2026
  4. 6.2.2 Global Treating Chronic Myeloid Leukemia by Phase Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Treating Chronic Myeloid Leukemia by Phase Sales Value (2021-2032)
  7. 6.3.2 North America Treating Chronic Myeloid Leukemia by Phase Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Treating Chronic Myeloid Leukemia by Phase Sales Value (2021-2032)
  10. 6.4.2 Europe Treating Chronic Myeloid Leukemia by Phase Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Treating Chronic Myeloid Leukemia by Phase Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Treating Chronic Myeloid Leukemia by Phase Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Treating Chronic Myeloid Leukemia by Phase Sales Value (2021-2032)
  16. 6.6.2 South America Treating Chronic Myeloid Leukemia by Phase Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Treating Chronic Myeloid Leukemia by Phase Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Treating Chronic Myeloid Leukemia by Phase Sales Value Share by Country, 2025 VS 2032
7 Treating Chronic Myeloid Leukemia by Phase Country-level Value Analysis
  1. 7.1 Global Treating Chronic Myeloid Leukemia by Phase Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Treating Chronic Myeloid Leukemia by Phase Sales Value by Country (2021-2032)
  3. 7.2.1 Global Treating Chronic Myeloid Leukemia by Phase Sales Value by Country (2021-2026)
  4. 7.2.2 Global Treating Chronic Myeloid Leukemia by Phase Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Treating Chronic Myeloid Leukemia by Phase Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Treating Chronic Myeloid Leukemia by Phase Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Treating Chronic Myeloid Leukemia by Phase Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Treating Chronic Myeloid Leukemia by Phase Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Treating Chronic Myeloid Leukemia by Phase Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Treating Chronic Myeloid Leukemia by Phase Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Treating Chronic Myeloid Leukemia by Phase Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Treating Chronic Myeloid Leukemia by Phase Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Treating Chronic Myeloid Leukemia by Phase Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Treating Chronic Myeloid Leukemia by Phase Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Treating Chronic Myeloid Leukemia by Phase Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Treating Chronic Myeloid Leukemia by Phase Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Treating Chronic Myeloid Leukemia by Phase Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Treating Chronic Myeloid Leukemia by Phase Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Treating Chronic Myeloid Leukemia by Phase Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Treating Chronic Myeloid Leukemia by Phase Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Treating Chronic Myeloid Leukemia by Phase Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Treating Chronic Myeloid Leukemia by Phase Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Treating Chronic Myeloid Leukemia by Phase Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Treating Chronic Myeloid Leukemia by Phase Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Treating Chronic Myeloid Leukemia by Phase Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Treating Chronic Myeloid Leukemia by Phase Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Treating Chronic Myeloid Leukemia by Phase Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Treating Chronic Myeloid Leukemia by Phase Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Treating Chronic Myeloid Leukemia by Phase Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Treating Chronic Myeloid Leukemia by Phase Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Treating Chronic Myeloid Leukemia by Phase Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Treating Chronic Myeloid Leukemia by Phase Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Treating Chronic Myeloid Leukemia by Phase Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Treating Chronic Myeloid Leukemia by Phase Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Treating Chronic Myeloid Leukemia by Phase Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Treating Chronic Myeloid Leukemia by Phase Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Treating Chronic Myeloid Leukemia by Phase Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Treating Chronic Myeloid Leukemia by Phase Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Treating Chronic Myeloid Leukemia by Phase Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Treating Chronic Myeloid Leukemia by Phase Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Treating Chronic Myeloid Leukemia by Phase Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Treating Chronic Myeloid Leukemia by Phase Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Treating Chronic Myeloid Leukemia by Phase Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Treating Chronic Myeloid Leukemia by Phase Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Treating Chronic Myeloid Leukemia by Phase Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Treating Chronic Myeloid Leukemia by Phase Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Treating Chronic Myeloid Leukemia by Phase Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Treating Chronic Myeloid Leukemia by Phase Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Treating Chronic Myeloid Leukemia by Phase Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Treating Chronic Myeloid Leukemia by Phase Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Treating Chronic Myeloid Leukemia by Phase Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Treating Chronic Myeloid Leukemia by Phase Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Treating Chronic Myeloid Leukemia by Phase Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Treating Chronic Myeloid Leukemia by Phase Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Treating Chronic Myeloid Leukemia by Phase Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Treating Chronic Myeloid Leukemia by Phase Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Treating Chronic Myeloid Leukemia by Phase Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Treating Chronic Myeloid Leukemia by Phase Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Treating Chronic Myeloid Leukemia by Phase Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Treating Chronic Myeloid Leukemia by Phase Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Treating Chronic Myeloid Leukemia by Phase Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Treating Chronic Myeloid Leukemia by Phase Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Treating Chronic Myeloid Leukemia by Phase Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Treating Chronic Myeloid Leukemia by Phase Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Treating Chronic Myeloid Leukemia by Phase Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Treating Chronic Myeloid Leukemia by Phase Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Treating Chronic Myeloid Leukemia by Phase Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Treating Chronic Myeloid Leukemia by Phase Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Treating Chronic Myeloid Leukemia by Phase Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Treating Chronic Myeloid Leukemia by Phase Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Treating Chronic Myeloid Leukemia by Phase Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Treating Chronic Myeloid Leukemia by Phase Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Treating Chronic Myeloid Leukemia by Phase Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Treating Chronic Myeloid Leukemia by Phase Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Treating Chronic Myeloid Leukemia by Phase Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Treating Chronic Myeloid Leukemia by Phase Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Treating Chronic Myeloid Leukemia by Phase Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Treating Chronic Myeloid Leukemia by Phase Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Treating Chronic Myeloid Leukemia by Phase Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Treating Chronic Myeloid Leukemia by Phase Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Treating Chronic Myeloid Leukemia by Phase Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Treating Chronic Myeloid Leukemia by Phase Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Treating Chronic Myeloid Leukemia by Phase Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Treating Chronic Myeloid Leukemia by Phase Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Treating Chronic Myeloid Leukemia by Phase Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Treating Chronic Myeloid Leukemia by Phase Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Treating Chronic Myeloid Leukemia by Phase Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Treating Chronic Myeloid Leukemia by Phase Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Chia Tai Tianqing Pharmaceutical
  2. 8.1.1 Chia Tai Tianqing Pharmaceutical Company Information
  3. 8.1.2 Chia Tai Tianqing Pharmaceutical Business Overview
  4. 8.1.3 Chia Tai Tianqing Pharmaceutical Treating Chronic Myeloid Leukemia by Phase Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Chia Tai Tianqing Pharmaceutical Treating Chronic Myeloid Leukemia by Phase Product Portfolio
  6. 8.1.5 Chia Tai Tianqing Pharmaceutical Recent Developments
  7. 8.2 Suzhou Thery Pharmaceutical
  8. 8.2.1 Suzhou Thery Pharmaceutical Company Information
  9. 8.2.2 Suzhou Thery Pharmaceutical Business Overview
  10. 8.2.3 Suzhou Thery Pharmaceutical Treating Chronic Myeloid Leukemia by Phase Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Suzhou Thery Pharmaceutical Treating Chronic Myeloid Leukemia by Phase Product Portfolio
  12. 8.2.5 Suzhou Thery Pharmaceutical Recent Developments
  13. 8.3 CSPC Ouyi Pharmaceutical
  14. 8.3.1 CSPC Ouyi Pharmaceutical Company Information
  15. 8.3.2 CSPC Ouyi Pharmaceutical Business Overview
  16. 8.3.3 CSPC Ouyi Pharmaceutical Treating Chronic Myeloid Leukemia by Phase Revenue and Gross Margin (2021-2026)
  17. 8.3.4 CSPC Ouyi Pharmaceutical Treating Chronic Myeloid Leukemia by Phase Product Portfolio
  18. 8.3.5 CSPC Ouyi Pharmaceutical Recent Developments
  19. 8.4 Qilu Pharmaceutical
  20. 8.4.1 Qilu Pharmaceutical Company Information
  21. 8.4.2 Qilu Pharmaceutical Business Overview
  22. 8.4.3 Qilu Pharmaceutical Treating Chronic Myeloid Leukemia by Phase Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Qilu Pharmaceutical Treating Chronic Myeloid Leukemia by Phase Product Portfolio
  24. 8.4.5 Qilu Pharmaceutical Recent Developments
  25. 8.5 Lunan Pharmaceutical
  26. 8.5.1 Lunan Pharmaceutical Company Information
  27. 8.5.2 Lunan Pharmaceutical Business Overview
  28. 8.5.3 Lunan Pharmaceutical Treating Chronic Myeloid Leukemia by Phase Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Lunan Pharmaceutical Treating Chronic Myeloid Leukemia by Phase Product Portfolio
  30. 8.5.5 Lunan Pharmaceutical Recent Developments
  31. 8.6 Hansoh Pharmaceutical
  32. 8.6.1 Hansoh Pharmaceutical Company Information
  33. 8.6.2 Hansoh Pharmaceutical Business Overview
  34. 8.6.3 Hansoh Pharmaceutical Treating Chronic Myeloid Leukemia by Phase Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Hansoh Pharmaceutical Treating Chronic Myeloid Leukemia by Phase Product Portfolio
  36. 8.6.5 Hansoh Pharmaceutical Recent Developments
  37. 8.7 Teva
  38. 8.7.1 Teva Company Information
  39. 8.7.2 Teva Business Overview
  40. 8.7.3 Teva Treating Chronic Myeloid Leukemia by Phase Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Teva Treating Chronic Myeloid Leukemia by Phase Product Portfolio
  42. 8.7.5 Teva Recent Developments
  43. 8.8 Takeda Pharmaceuticals
  44. 8.8.1 Takeda Pharmaceuticals Company Information
  45. 8.8.2 Takeda Pharmaceuticals Business Overview
  46. 8.8.3 Takeda Pharmaceuticals Treating Chronic Myeloid Leukemia by Phase Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Takeda Pharmaceuticals Treating Chronic Myeloid Leukemia by Phase Product Portfolio
  48. 8.8.5 Takeda Pharmaceuticals Recent Developments
  49. 8.9 Sun Pharmaceuticals
  50. 8.9.1 Sun Pharmaceuticals Company Information
  51. 8.9.2 Sun Pharmaceuticals Business Overview
  52. 8.9.3 Sun Pharmaceuticals Treating Chronic Myeloid Leukemia by Phase Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Sun Pharmaceuticals Treating Chronic Myeloid Leukemia by Phase Product Portfolio
  54. 8.9.5 Sun Pharmaceuticals Recent Developments
  55. 8.10 Sawai Pharmaceutical
  56. 8.10.1 Sawai Pharmaceutical Company Information
  57. 8.10.2 Sawai Pharmaceutical Business Overview
  58. 8.10.3 Sawai Pharmaceutical Treating Chronic Myeloid Leukemia by Phase Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Sawai Pharmaceutical Treating Chronic Myeloid Leukemia by Phase Product Portfolio
  60. 8.10.5 Sawai Pharmaceutical Recent Developments
  61. 8.11 Pfizer
  62. 8.11.1 Pfizer Company Information
  63. 8.11.2 Pfizer Business Overview
  64. 8.11.3 Pfizer Treating Chronic Myeloid Leukemia by Phase Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Pfizer Treating Chronic Myeloid Leukemia by Phase Product Portfolio
  66. 8.11.5 Pfizer Recent Developments
  67. 8.12 Novartis
  68. 8.12.1 Novartis Company Information
  69. 8.12.2 Novartis Business Overview
  70. 8.12.3 Novartis Treating Chronic Myeloid Leukemia by Phase Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Novartis Treating Chronic Myeloid Leukemia by Phase Product Portfolio
  72. 8.12.5 Novartis Recent Developments
  73. 8.13 Mylan
  74. 8.13.1 Mylan Company Information
  75. 8.13.2 Mylan Business Overview
  76. 8.13.3 Mylan Treating Chronic Myeloid Leukemia by Phase Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Mylan Treating Chronic Myeloid Leukemia by Phase Product Portfolio
  78. 8.13.5 Mylan Recent Developments
  79. 8.14 Lupin
  80. 8.14.1 Lupin Company Information
  81. 8.14.2 Lupin Business Overview
  82. 8.14.3 Lupin Treating Chronic Myeloid Leukemia by Phase Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Lupin Treating Chronic Myeloid Leukemia by Phase Product Portfolio
  84. 8.14.5 Lupin Recent Developments
  85. 8.15 Hetero
  86. 8.15.1 Hetero Company Information
  87. 8.15.2 Hetero Business Overview
  88. 8.15.3 Hetero Treating Chronic Myeloid Leukemia by Phase Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Hetero Treating Chronic Myeloid Leukemia by Phase Product Portfolio
  90. 8.15.5 Hetero Recent Developments
  91. 8.16 Eugia Pharma
  92. 8.16.1 Eugia Pharma Company Information
  93. 8.16.2 Eugia Pharma Business Overview
  94. 8.16.3 Eugia Pharma Treating Chronic Myeloid Leukemia by Phase Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Eugia Pharma Treating Chronic Myeloid Leukemia by Phase Product Portfolio
  96. 8.16.5 Eugia Pharma Recent Developments
  97. 8.17 Dr. Reddy's Laboratories
  98. 8.17.1 Dr. Reddy's Laboratories Company Information
  99. 8.17.2 Dr. Reddy's Laboratories Business Overview
  100. 8.17.3 Dr. Reddy's Laboratories Treating Chronic Myeloid Leukemia by Phase Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Dr. Reddy's Laboratories Treating Chronic Myeloid Leukemia by Phase Product Portfolio
  102. 8.17.5 Dr. Reddy's Laboratories Recent Developments
  103. 8.18 Bristol Myers Squibb
  104. 8.18.1 Bristol Myers Squibb Company Information
  105. 8.18.2 Bristol Myers Squibb Business Overview
  106. 8.18.3 Bristol Myers Squibb Treating Chronic Myeloid Leukemia by Phase Revenue and Gross Margin (2021-2026)
  107. 8.18.4 Bristol Myers Squibb Treating Chronic Myeloid Leukemia by Phase Product Portfolio
  108. 8.18.5 Bristol Myers Squibb Recent Developments
  109. 8.19 Apotex
  110. 8.19.1 Apotex Company Information
  111. 8.19.2 Apotex Business Overview
  112. 8.19.3 Apotex Treating Chronic Myeloid Leukemia by Phase Revenue and Gross Margin (2021-2026)
  113. 8.19.4 Apotex Treating Chronic Myeloid Leukemia by Phase Product Portfolio
  114. 8.19.5 Apotex Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst